首页 | 本学科首页   官方微博 | 高级检索  
检索        

孟鲁司特钠佐治儿童咳嗽变异性哮喘临床疗效分析
引用本文:宋晓彤,马路一.孟鲁司特钠佐治儿童咳嗽变异性哮喘临床疗效分析[J].徐州医学院学报,2014(2):115-118.
作者姓名:宋晓彤  马路一
作者单位:[1]大连医科大学研究生院2011级,辽宁 大连116044 [2]大连医科大学附属第一医院儿科,辽宁 大连116011
摘    要:目的:观察孟鲁司特钠佐治儿童咳嗽变异性哮喘( CVA)的疗效及安全性。方法将128例儿童CVA病例随机分为2组。对照组64例采用盐酸丙卡特罗治疗,连续口服7天,患儿咳嗽缓解后停用,同时给予布地奈德气雾剂吸入;观察组64例在对照组治疗的基础上,加用孟鲁司特钠咀嚼片进行治疗,2组疗程均为4周。评价分析2组临床疗效、安全性,比较3个月内复发率。结果观察组总有效率为93.75%,优于对照组的79.69%( P<0.05);观察组临床症状缓解时间、症状消失时间均短于对照组(P<0.01);观察组血嗜酸性粒细胞(EOS)比例下降程度及最大呼气峰流速(PEF)升高值明显高均优于对照组(P<0.01);2组均未发生严重不良反应(P>0.05);随访3个月内观察组复发率明显低于对照组( P<0.05)。结论口服孟鲁司特钠辅助治疗儿童CVA有效,且无严重不良反应,复发率低,依从性好,值得临床推广。

关 键 词:孟鲁司特钠  咳嗽变异性哮喘  儿童

Clinical analysis of montelukast sodium in the treatment of children with cough variant asthma
SONG Xiaotong,MA Luyi.Clinical analysis of montelukast sodium in the treatment of children with cough variant asthma[J].Acta Academiae Medicinae Xuzhou,2014(2):115-118.
Authors:SONG Xiaotong  MA Luyi
Institution:1. Grade 2011, Graduate School, Dalian Medical University, Dalian, Liaoning 116044, China; 2. Department of Pediatrics, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011)
Abstract:Objective To investigate the efficacy and safety of montelukast sodium in the treatment of children with cough variant asthma ( CVA) .Methods The 128 cases of children with CVA were randomly divided into two groups . 64 case in the control group were treated by taking procaterol hydrochloride orally for 7 days and stoped when cough was relieved.Budesonide aerosol inhalation was given at the same time .64 case in the observation group were treated by montelukast sodium chewable tablets , based on treatment in the control group .The clinical efficacy , safty and relapse rate within 3 months were evaluated after a course of treatment for 4 weeks in both groups .Results The total effective rate in the observation group was 93.75%, better than in the control group of 79.69%(P〈0.05).The time to clinical symptoms relief and symptoms disappearance was shorter in the observation group than in the control group (P〈0.01). The drop of blood eosinophils ( EOS) ratio and increase in peak expiratory flow ( PEF) values were significantly better in the observation group than in the control group ( P〈0 .01 ) .Severe adverse reactions were not observed in both groups (P〉0.05).3 months followed-up showed that the recurrence rate was lower in the observation group than in the con-trol group (P〈0.05).Conclusion It is safe and effective to take montelukast as adjuvant therapy for children with CVA, with low recurrence rate , no serious adverse reactions , and good compliance .So, it is worthy of clinical applica-tion.
Keywords:montelukast  cough variant asthma  children
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号